Prefer Cipla, Sun Pharma, Dr Reddys: Phani Sekhar

Phani Sekhar of Angel Broking told CNBC-TV18, "Pharma is one business where I will be positive in the short-term but I am uncertain in the long-term. So I guess if you are looking as a long-term investor then my honest assessment is we don’t know what happens to Ranbaxy Laboratories in a long-term. In the pharmaceutical space one can be with Cipla or Sun Pharmaceutical or Dr Reddy’s Laboratories. These are the kind of companies that should do well over the longer-term."

On March 10, 2014 Dr Reddys Laboratories closed at Rs 2,689.15, down Rs 37.10, or 1.36 percent.

The share touched its 52-week high Rs 2,939.80 and 52-week low Rs 1,786.50 on 28 February, 2014 and 28 March, 2013, respectively.